Sept 27 (Reuters) - Pfizer Inc said on Monday it had dosed the first patient in a trial testing a flu vaccine based on messenger RNA, the same technology used in the COVID-19 shots made by the U.S. drugmaker and BioNTech. (Reporting by Manas Mishra in Bengaluru; Editing by Shinjini Ganguli)
Stock market news
- Stock
- Stock market news
- Economy
- Pfizer begins study of mRNA flu vaccine